Patients with AIDS at increased risk of developing age-related macular degeneration

May 4, 2015, The Mount Sinai Hospital
eye

Patients with acquired immunodeficiency syndrome (AIDS) have a four-fold increase in their risk of developing intermediate-stage age-related macular degeneration (AMD) compared to people of the same age who are not infected with HIV, according to results from the Longitudinal Study of the Ocular Complications of AIDS (LSOCA) presented today at the 2015 ARVO Annual Meeting in Denver, CO. The results of the study, led by the National Eye Institute-funded Studies of the Ocular Complications of AIDS Research Group, were also published online in the American Journal of Ophthalmology.

"With HIV and AIDS living longer than ever before, they are at an increased risk of developing several age-related diseases at an earlier age than HIV-uninfected people including cardiovascular disease and diabetes," said Douglas A. Jabs, MD, MBA, Professor of Ophthalmology and Medicine at the Icahn School of Medicine at Mount Sinai, and the lead author of the new study. "Their increased risk for age-related diseases in general led us to analyze how these patients are impacted by one of the most common age-related eye diseases, ."

AMD is the leading cause of visual impairment and blindness in people over 65 years old and is the result of damage to the central area of the retina called the macula, which is responsible for good central vision. AMD is described in stages - early, intermediate, and late - with vision loss occurring in late-stage AMD, either from atrophy or abnormal new blood vessels. HIV-uninfected persons with intermediate-stage AMD are at an of progressing to late-stage AMD, but typically do not have loss of vision from the AMD.

To determine how AIDS may contribute to AMD, Dr. Jabs and colleagues enrolled 1,825 patients ages 13-73 years with AIDS at 19 sites in United States between 1998 - 2011. The investigators graded retinal photographs for AMD and compared participants in the LSOCA cohort to published data on an HIV-uninfected, age-matched population from the Beaver Dam Offspring Study, which also graded retinal photographs for AMD features. The results showed that the prevalence of intermediate-stage AMD in patients with AIDS was nearly 10 percent and, when adjusted for any age differences, was approximately four-fold greater than that in the Beaver Dam Study.

The researchers also determined that the increased prevalence of AMD in the LSOCA cohort was not related to any drug or class of drugs used to treat HIV infection. Rather they point out that antiretroviral-treated, immune-restored, HIV-infected patients do not have normal immune systems; instead and on average they have immunologic changes similar to those seen in patients who are not infected who are older than 70 years of age, a phenomenon termed "immunosenescence."

"Although the underlying mechanism leading to this increase in AMD in persons with AIDS is not yet known, it may relate to the state of chronic immune activation and systemic inflammation seen in these patients," said Dr. Jabs.

Dr. Jabs and colleagues note that further exploration of these findings may provide the opportunity to better understand the roles of immunosenescence and systemic inflammation in the development of AMD, which in turn could lead new treatments. The results also add to the growing body of research suggesting that antiretroviral therapy-treated, immunorestored, HIV-infected persons may experience accelerated and accentuated aging.

Explore further: Progression of age-related macular degeneration in one eye then fellow eye

Related Stories

Progression of age-related macular degeneration in one eye then fellow eye

October 23, 2014
Having age-related macular degeneration (AMD) in one eye was associated with an increased incidence of AMD and accelerated progression of the debilitating disease in the other eye, writes author Ronald E. Gangnon, Ph.D., ...

HIV/AIDS drugs could be repurposed to treat AMD

November 20, 2014
A landmark study published today in the journal Science by an international group of scientists, led by the laboratory of Dr. Jayakrishna Ambati, professor & vice chair of the Department of Ophthalmology & Visual Sciences ...

Some high blood pressure drugs may be associated with increased risk of vision-threatening disease

May 28, 2014
There may be a connection between taking vasodilators and developing early-stage age-related macular degeneration (AMD), the leading cause of vision loss and blindness among Americans who are age 65 and older, according to ...

Seniors shouldn't be blinded by old notions of eye disease

February 3, 2015
Age-related Macular Degeneration (AMD) is the leading cause of blindness among older Americans, but new treatments have dramatically changed the course of this disease over the last 10 years, making AMD more manageable than ...

In mice and men: Laser treatment reverses effects of early age-related macular degeneration

February 2, 2015
A new technique reported in the February 2015 issue of The FASEB Journal suggests that during early stages, it might be possible to reverse age-related macular degeneration, a leading cause of blindness that is currently ...

Scientists discover unique risk variants of age-related macular degeneration in East Asians

February 25, 2015
Age-related macular degeneration (AMD) is a major cause of blindness in the elderly in Singapore and worldwide. By 2040, global projected cases of AMD are 288 million, with the largest number of cases in Asia (113 million).

Recommended for you

Injection improves vision in a form of childhood blindness

December 17, 2018
A new treatment for patients with a form of congenital retinal blindness has shown success in improving vision, according to results published today in Nature Medicine led by researchers at the Scheie Eye Institute in the ...

Researchers report vision-based neurotransmitter events for the first time

November 27, 2018
How does vision work, and what happens in the brain during the process? As simple as this question may sound, it has yet to be scientifically clarified. Dr. Valentin Riedl of the Technical University of Munich (TUM) and his ...

Minimally invasive retinal detachment has better outcomes, clinical trial findings

November 26, 2018
A minimally invasive treatment for retinal detachment gives patients sharper vision, less distortion and reduced side-effects, according to the findings of a randomized controlled trial performed at St. Michael's Hospital ...

Scientists combine technologies to view the retina in unprecedented detail

November 14, 2018
By combining two imaging modalities—adaptive optics and angiography—investigators at the National Eye Institute (NEI) can see live neurons, epithelial cells, and blood vessels deep in the eye's light-sensing retina. Resolving ...

Eyepatch with dissolvable needles used to treat eye disease

November 12, 2018
A team of researchers affiliated with several institutions in Singapore has developed an eyepatch with dissolvable needles for use in treating eye diseases. In their paper published in the journal Nature Communications, the ...

Calcifications in the eye increase risk for progression to advanced AMD by more than six times

November 8, 2018
Calcified nodules in the retina are associated with progression to late stages of age-related macular degeneration (AMD). Experts from Queen's University Belfast, working in partnership with the University of Alabama of Birmingham ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.